Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciae405 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Kevin C Ma und 59 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Hospitalization, Vaccine Efficacy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, NCATS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Assessing variant-specific coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as “JN lineages”), emerged in late 2023 and exhibited substantial divergence from co-circulating XBB lineages.
Methods
We analyzed patients hospitalized with COVID-19–like illness at 26 hospitals in 20 US states admitted 18 October 2023–9 March 2024. Using a test-negative, case-control design, we estimated effectiveness of an updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression.
Results
A total of 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4580 control patients were included. VE in the first 7–89 days after receipt of an updated dose was 54.2% (95% confidence interval [CI], 36.1–67.1%) against XBB lineage hospitalization and 32.7% (95% CI, 1.9–53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR], .80; 95% CI, .46–1.38) and IMV or death (aOR, .69; 95% CI, .34–1.40) were not significantly different among JN compared with XBB lineage hospitalizations.
Conclusions
Updated 2023–2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
- University of Michigan, Ann Arbor, Michigan, USA.
- Baylor Scott & White Health, Dallas, Texas, USA.
- Baylor Scott & White, Temple, Texas, USA.
- Department of Medicine, Intermountain Medical Center, Murray, Utah, USA.
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: Kevin C Ma
Förderung
- Intramural CDC HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- Centers Disease Control and Prevention
Zitieren
APA
Ma, K. C., Surie, D., Lauring, A. S., Martin, E. T., Leis, A. M., Papalambros, L., Gaglani, M., Columbus, C., Gottlieb, R. L., Ghamande, S., Peltan, I. D., Brown, S. M., Ginde, A. A., Mohr, N. M., Gibbs, K. W., Hager, D. N., Saeed, S., Prekker, M. E., Gong, M. N., …, & Dawood, F. S. (2026). Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae405
Vancouver
Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, et al. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciae405
BibTeX
@article{Ma2026,
author = {Ma, Kevin C and Surie, Diya and Lauring, Adam S and Martin, Emily T and Leis, Aleda M and Papalambros, Leigh and Gaglani, Manjusha and Columbus, Christie and Gottlieb, Robert L and Ghamande, Shekhar and Peltan, Ithan D and Brown, Samuel M and Ginde, Adit A and Mohr, Nicholas M and Gibbs, Kevin W and Hager, David N and Saeed, Safa and Prekker, Matthew E and Gong, Michelle Ng and Mohamed, Amira and Johnson, Nicholas J and Srinivasan, Vasisht and Steingrub, Jay S and Khan, Akram and Hough, Catherine L and Duggal, Abhijit and Wilson, Jennifer G and Qadir, Nida and Chang, Steven Y and Mallow, Christopher and Kwon, Jennie H and Parikh, Bijal and Exline, Matthew C and Vaughn, Ivana A and Ramesh, Mayur and Safdar, Basmah and Mosier, Jarrod and Harris, Estelle S and Shapiro, Nathan I and Felzer, Jamie and Zhu, Yuwei and Grijalva, Carlos G and Halasa, Natasha and Chappell, James D and Womack, Kelsey N and Rhoads, Jillian P and Baughman, Adrienne and Swan, Sydney A and Johnson, Cassandra A and Rice, Todd W and Casey, Jonathan D and Blair, Paul W and Han, Jin H and Ellington, Sascha and Lewis, Nathaniel M and Thornburg, Natalie and Paden, Clinton R and Atherton, Lydia J and Self, Wesley H and Dawood, Fatimah S},
title = {Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciae405}
}
EUVIMED